Singh Lata, Pushker Neelam, Sen Seema, Singh Mithalesh K, Chauhan Feeroj A, Kashyap Seema
Department of Ocular Pathology, Dr. R. P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Department of Ophthalmology, Dr. R. P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Clin Exp Ophthalmol. 2015 Aug;43(6):550-7. doi: 10.1111/ceo.12517. Epub 2015 May 13.
Retinoblastoma is evolving, but it is still a therapeutic challenge for pediatric oncologists. Polo-like kinases (PLKs) plays an important role in cell cycle events. They play a crucial role in cell proliferation which may lead to tumour formation. The objective of this study is to investigate the role of PLK1 and PLK3 proteins in human retinoblastoma tissues.
Non-randomized, prospective study was performed in the Dr R. P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
This study included 74 primary enucleated retinoblastoma tissues.
Expression of PLK1 and PLK3 protein were assessed in primary enucleated retinoblastoma tissues by immunohistochemistry and western blotting.
Expression of PLK1 and PLK3 protein were correlated with clinical and histopathological parameters, tumour staging and overall survival of patients.
Immunohistochemical results revealed expression of PLK1 in 47/74 (63.51%) cases and PLK3 in 31/74 (41.89%) cases. Western blotting confirmed the immunoreactivity results. Expression of PLK1 showed correlation with poor differentiation and tumour invasion. In addition, PLK1 was statistically significant with massive choroidal invasion, whereas PLK3 did not correlate with any of the clinical or histopathological parameters. There was no statistical correlation in the overall survival of patients with PLK1 and PLK3 expression.
PLK1 expression was associated with poor tumour differentiation and histopathological high-risk factors. These proteins may be involved in tumorigenesis and progression of disease. These results suggest that PLK1 may act as a potential therapeutic target and a promising marker for developing potent small molecule inhibitors of PLK isoforms in retinoblastoma.
视网膜母细胞瘤在不断演变,但对于儿科肿瘤学家而言仍是一项治疗挑战。Polo样激酶(PLKs)在细胞周期事件中发挥重要作用。它们在可能导致肿瘤形成的细胞增殖中起着关键作用。本研究的目的是探讨PLK1和PLK3蛋白在人视网膜母细胞瘤组织中的作用。
在印度新德里全印度医学科学研究所R.P.眼科科学中心进行了非随机前瞻性研究。
本研究纳入了74例原发性眼球摘除的视网膜母细胞瘤组织。
通过免疫组织化学和蛋白质印迹法评估原发性眼球摘除的视网膜母细胞瘤组织中PLK1和PLK3蛋白的表达。
PLK1和PLK3蛋白的表达与患者的临床和组织病理学参数、肿瘤分期及总生存期相关。
免疫组织化学结果显示,74例中有47例(63.51%)表达PLK1,31例(41.89%)表达PLK3。蛋白质印迹法证实了免疫反应结果。PLK1的表达与低分化和肿瘤侵袭相关。此外,PLK1与脉络膜大面积侵袭具有统计学意义,而PLK3与任何临床或组织病理学参数均无相关性。PLK1和PLK3表达的患者总生存期无统计学相关性。
PLK1表达与肿瘤低分化及组织病理学高危因素相关。这些蛋白可能参与疾病的肿瘤发生和进展。这些结果表明,PLK1可能作为一种潜在的治疗靶点,以及开发视网膜母细胞瘤中PLK亚型有效小分子抑制剂的有前景的标志物。